FAMAR Group Acquires Sterile Manufacturing Facility
FAMAR Group, a prominent player in the European pharmaceutical contract development and manufacturing organization (CDMO) sector, has made significant strides with its recent acquisition of a sterile production site located in Homburg, Germany. This acquisition comes as a strategic decision that propels FAMAR's growth trajectory, allowing it to expand its reach and improve its capabilities in producing high-value dosage forms, especially in aseptic and lyophilized fill & finish processes.
Significance of the Homburg Facility
The Homburg facility is not just another manufacturing site; it has received extensive investments and modernization, ensuring it adheres to the highest standards of production. Once operational, FAMAR will boast a total of seven manufacturing facilities scattered across Europe. These enhancements are designed to provide customers with adaptable and high-quality production solutions, leveraging the latest technology and established best practices in the pharmaceutical industry.
Expert Insight from Company Leadership
In a statement highlighting the significance of this acquisition, Konstantinos Rengis, CEO of FAMAR Group, expressed enthusiasm for the Homburg site's features. Rengis remarked, "The Homburg site offers world-class sterile infrastructure, newly installed QC and microbiology laboratories, and a skilled workforce. This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together."
Impact on Employment and Future Growth
As a result of the acquisition, approximately 100 employees from MiP Pharma will transition to FAMAR. This move is critical not only for retaining industry knowledge but also for assuring continuity in operations. The Homburg site is aimed to evolve into a multi-customer CDMO platform, which resonates with FAMAR's ambition to lead in complex and high-value pharmaceutical manufacturing.
Collaboration with MiP Pharma
Dr. Friedrich Sernetz, the CEO of MiP Pharma, shared insights about this transaction, stating, "Thanks to the investments, the Homburg facility has become an attractive site for global pharmaceutical specialists. With FAMAR, we have found a buyer who will further develop the site. This secures jobs and lays the foundation for future growth. At the same time, we can focus on our core competency – the marketing of our medicines – and accelerate our growth."
Strategic Objectives and Future Directions
This acquisition further reinforces FAMAR’s commitment to enhancing its global service offerings in the healthcare sector. Matthew Strassberg, a partner at MidEuropa, highlighted the efforts to support FAMAR on its journey towards serving its international clientele. Strassberg noted, "We are delighted to support FAMAR on its mission to serve its global customer base in a flexible and comprehensive way. The acquisition of the Homburg site demonstrates MidEuropa's strong commitment to support FAMAR as it accelerates its expansion into value-added formulations and service offerings."
About FAMAR Group
FAMAR Group stands out as a leading European provider of pharmaceutical and cosmetic manufacturing and development services. With a remarkable legacy spanning 75 years, FAMAR is involved in delivering high-quality dosage forms, which include sterile liquids, solids, and semi-solids. The company creates value for its diverse clientele spread across various markets. FAMAR operates in multiple European countries, employing over 1,850 individuals across a widespread network of six production facilities and two R&D centers. The company’s vast portfolio consists of over 1,700 different products catering to more than 80 international markets.
About MiP Pharma Group
MiP Pharma Group specializes in marketing prescription generics, particularly antibiotics, as well as over-the-counter medications and medical devices. The company concentrates on the hospital sector while addressing specific specialist groups. With a dedicated workforce of over 200 employees and around 400 marketing authorizations, MiP Pharma achieved notable sales figures recently. Since late 2020, it has been backed by a Berlin-based financial investor, encouraging ongoing developments in its core activities.
Frequently Asked Questions
What is the main goal of FAMAR's recent acquisition?
The primary goal is to enhance FAMAR's capabilities in high-value dosage forms, particularly in aseptic and lyophilized fill & finish processes.
How many facilities will FAMAR operate after this acquisition?
After acquiring the Homburg site, FAMAR will operate a total of seven production facilities across Europe.
How many employees will transition to FAMAR from MiP Pharma?
Approximately 100 employees from MiP Pharma will join FAMAR as part of the acquisition.
What key features does the Homburg site offer?
The Homburg site boasts world-class sterile infrastructure, state-of-the-art QC, and microbiology laboratories, along with a skilled workforce.
What does FAMAR specialize in?
FAMAR specializes in pharmaceutical and cosmetic manufacturing, delivering high-quality dosage forms and serving a multitude of markets globally.
